Company
Cyxone AB
Headquarters: Malmo, Sweden
Employees: 8
Market Cap
kr22.8 Million
SEK as of Jan. 1, 2024
US$2.3 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Cyxone AB has the following listings and related stock indices.
Stock: OMX: CYXO wb_incandescent
Stock: FSX: 4CX wb_incandescent